Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM.

J Clin Pharmacol. 2019 Feb 7. doi: 10.1002/jcph.1387. [Epub ahead of print] Review.

PMID:
30730563
2.

Epilepsy and Cannabis: A Literature Review.

Zaheer S, Kumar D, Khan MT, Giyanwani PR, Kiran F.

Cureus. 2018 Sep 10;10(9):e3278. doi: 10.7759/cureus.3278. Review.

3.

Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.

Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, Shah N, Wu L, Haq K, Solanki S, Kim D, Ahmed A.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):149-156. doi: 10.1097/MEG.0000000000001263.

PMID:
30234644
4.

Cannabis in liver disorders: a friend or a foe?

Goyal H, Rahman MR, Perisetti A, Shah N, Chhabra R.

Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1283-1290. doi: 10.1097/MEG.0000000000001256. Review.

PMID:
30169449
5.

Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.

Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, Truong L, Lawson JA.

Med J Aust. 2018 Aug 3;209(5):217-221. Epub 2018 Aug 13.

PMID:
30092753
6.

Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury.

Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Haskó G, Mechoulam R, Gao B, Pacher P.

Sci Rep. 2017 Sep 21;7(1):12064. doi: 10.1038/s41598-017-10924-8.

7.

Cannabinoids as Anticancer Drugs.

Ramer R, Hinz B.

Adv Pharmacol. 2017;80:397-436. doi: 10.1016/bs.apha.2017.04.002. Epub 2017 Jun 12. Review.

PMID:
28826542
8.

Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.

Arellano AL, Papaseit E, Romaguera A, Torrens M, Farré M.

CNS Neurol Disord Drug Targets. 2017;16(5):554-566. doi: 10.2174/1871527316666170413104516. Review.

PMID:
28412920
9.

Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.

Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, Laish I, Benjaminov F, Konikoff FM.

Dig Dis Sci. 2017 Jun;62(6):1615-1620. doi: 10.1007/s10620-017-4540-z. Epub 2017 Mar 27.

PMID:
28349233
10.

Potential of Cannabidiol for the Treatment of Viral Hepatitis.

Lowe HI, Toyang NJ, McLaughlin W.

Pharmacognosy Res. 2017 Jan-Mar;9(1):116-118. doi: 10.4103/0974-8490.199780.

11.

An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.

Pagano E, Capasso R, Piscitelli F, Romano B, Parisi OA, Finizio S, Lauritano A, Marzo VD, Izzo AA, Borrelli F.

Front Pharmacol. 2016 Oct 4;7:341. eCollection 2016.

12.

GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis.

Kargl J, Andersen L, Hasenöhrl C, Feuersinger D, Stančić A, Fauland A, Magnes C, El-Heliebi A, Lax S, Uranitsch S, Haybaeck J, Heinemann A, Schicho R.

Br J Pharmacol. 2016 Jan;173(1):142-54. doi: 10.1111/bph.13345. Epub 2015 Nov 25.

13.

HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Haj CG, Sumariwalla PF, Hanuš L, Kogan NM, Yektin Z, Mechoulam R, Feldmann M, Gallily R.

J Pharmacol Exp Ther. 2015 Oct;355(1):66-75. doi: 10.1124/jpet.115.226100. Epub 2015 Aug 13.

14.

Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.

Silvestri C, Paris D, Martella A, Melck D, Guadagnino I, Cawthorne M, Motta A, Di Marzo V.

J Hepatol. 2015 Jun;62(6):1382-90. doi: 10.1016/j.jhep.2015.01.001. Epub 2015 Jan 13.

PMID:
25595882
15.

Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy.

Yang L, Rozenfeld R, Wu D, Devi LA, Zhang Z, Cederbaum A.

Free Radic Biol Med. 2014 Mar;68:260-7. doi: 10.1016/j.freeradbiomed.2013.12.026. Epub 2014 Jan 4.

16.

Changes on metabolic parameters induced by acute cannabinoid administration (CBD, THC) in a rat experimental model of nutritional vitamin A deficiency.

El Amrani L, Porres JM, Merzouki A, Louktibi A, Aranda P, López-Jurado M, Urbano G.

Nutr Hosp. 2013 May-Jun;28(3):857-67. doi: 10.3305/nh.2013.28.3.6430.

17.

Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol.

Hegde VL, Nagarkatti PS, Nagarkatti M.

PLoS One. 2011 Apr 1;6(4):e18281. doi: 10.1371/journal.pone.0018281.

18.

Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.

Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, Haskó G, Mechoulam R, Pacher P.

Free Radic Biol Med. 2011 May 15;50(10):1368-81. doi: 10.1016/j.freeradbiomed.2011.02.021. Epub 2011 Mar 11.

19.

Endocannabinoids in liver disease.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G.

Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077. Review.

20.

Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.

Avraham Y, Grigoriadis N, Poutahidis T, Vorobiev L, Magen I, Ilan Y, Mechoulam R, Berry E.

Br J Pharmacol. 2011 Apr;162(7):1650-8. doi: 10.1111/j.1476-5381.2010.01179.x.

Supplemental Content

Loading ...
Support Center